1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. Projects must be relevant to at least one of the FY26 JWMRP focus areas.Distinctive Features:To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.An MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO) is available to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/proposal materials.
Funding Opportunity Number: HT942526JWMRPMMRDA. Assistance Listing: 12.420. Funding Instrument: CA,G,O,PC. Category: ST. Award Amount: $8.8M total program funding.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $8.8M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Joint Warfighter Medical, Military Medical Research and Development Award are due November 16, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Joint Warfighter Medical, Military Medical Research and Development Award is offered by Dept. of the Army -- USAMRAA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
The Long Range BAA is ONR's omnibus front door and the single most useful entry point for researchers who want Navy funding but are not responding to a named topic. It solicits Long-Range Science and Technology projects aimed at enhancing Navy and Marine Corps operations across science and engineering disciplines, and it is jointly issued with ONR Global and the Marine Corps Warfighting Laboratory - which matters because ONRG opens the door to non-U.S. performers and MCWL brings a distinct expeditionary problem set. For AI proposers the alignment is strong: ONR's 2026 Science and Technology Strategy names AI and autonomy as the organisation's top research focus, spanning machine learning, adversarial AI, intelligent agents, autonomous systems, and modelling and simulation. The strategy is built around a FEED at Speed framework and ties every research programme to a transition path, so proposals that articulate how a capability reaches the fleet are advantaged over those that stop at publication. ONR has additionally launched a strategic initiative to use AI to conduct basic and applied research rather than only to research AI for naval use cases, which opens space for AI-for-science proposals inside a defence portfolio. Eligibility is deliberately wide - all responsible sources from academia, industry and the research community worldwide may submit, and both small and large businesses compete, with the applicable SBA size standard at 1,000 employees. ONR does not publish per-award amounts. Submissions go through the ONR Submission Portal; FedConnect is no longer accepted as of Amendment 0004. The response deadline has been extended to 30 September 2026; the primary contact is Matthew Murray.
Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. Projects must be relevant to at least one of the FY26 JWMRP focus areas.Distinctive Features:To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.An MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO) is available to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/proposal materials. Funding Opportunity Number: HT942526JWMRPMMRDA. Assistance Listing: 12.420. Funding Instrument: CA,G,O,PC. Category: ST. Award Amount: $8.8M total program funding.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article